Peter Ratcliffe
Director/Board Member at IMMUNOCORE HOLDINGS PLC
Net worth: 19 314 $ as of 29/04/2024
Peter Ratcliffe active positions
Companies | Position | Start | End |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC | Director/Board Member | 31/10/2020 | - |
Independent Dir/Board Member | 31/10/2020 | - | |
ReOx Ltd.
ReOx Ltd. Pharmaceuticals: MajorHealth Technology ReOx Ltd. discovers and develops drugs. It provides novel treatments for disease by controlling the actvity of hypoxia inducible factor. The company was founded by Christopher W. Pugh, Patrick Maxwell, Peter J. Ratcliffe, and Christopher J. Schofield in June 2003 and is headquartered in Thame, the United Kingdom. | Director/Board Member | 31/05/2003 | - |
Founder | 31/05/2003 | - | |
The Francis Crick Institute Ltd.
The Francis Crick Institute Ltd. Medical/Nursing ServicesHealth Services The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - | - |
European Molecular Biology Organization | Corporate Officer/Principal | - | - |
University of Oxford | Corporate Officer/Principal | - | - |
American Academy of Arts & Sciences
American Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services The American Academy of Arts & Sciences is an organization that honors excellence and brings together leaders. The non-profit company is based in Cambridge, MA. | Corporate Officer/Principal | - | - |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Director/Board Member | - | - |
Target Discovery Institute | Director/Board Member | - | - |
Career history of Peter Ratcliffe
Statistics
International
United Kingdom | 7 |
Germany | 2 |
United States | 2 |
Operational
Director/Board Member | 4 |
Corporate Officer/Principal | 4 |
Founder | 1 |
Sectoral
Health Technology | 4 |
Health Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
IMMUNOCORE HOLDINGS PLC | Health Technology |
Private companies | 6 |
---|---|
ReOx Ltd.
ReOx Ltd. Pharmaceuticals: MajorHealth Technology ReOx Ltd. discovers and develops drugs. It provides novel treatments for disease by controlling the actvity of hypoxia inducible factor. The company was founded by Christopher W. Pugh, Patrick Maxwell, Peter J. Ratcliffe, and Christopher J. Schofield in June 2003 and is headquartered in Thame, the United Kingdom. | Health Technology |
The Francis Crick Institute Ltd.
The Francis Crick Institute Ltd. Medical/Nursing ServicesHealth Services The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom. | Health Services |
European Molecular Biology Organization | |
American Academy of Arts & Sciences
American Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services The American Academy of Arts & Sciences is an organization that honors excellence and brings together leaders. The non-profit company is based in Cambridge, MA. | Commercial Services |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Health Technology |
Target Discovery Institute |
- Stock Market
- Insiders
- Peter Ratcliffe
- Experience